1-4 of 4
Nicole Brousse, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enteropathy-Associated T-Cell Lymphoma Type I, But Not Refractory Celiac Disease, Strongly Expresses CD30 and Might Benefit From Brentuximab Vedotin

David Sibon, MD, PhD, Georgia Malamut, MD, PhD, Virginie Verkarre, MD, PhD, Coralie Derrieux, MD, Isabelle Radford, MD, Bertrand Meresse, PhD, Elizabeth Macintyre, MD, PhD, Christophe Cellier, MD, PhD, Nadine Cerf-Bensussan, MD, PhD, Nicole Brousse, M.D., Olivier Hermine
Journal: Blood
Blood (2013) 122 (21): 4252.
https://doi.org/10.1182/blood.V122.21.4252.4252
Published: 2013
Journal Articles

High Level of CD71 Expression On Neoplastic B Cells At Diagnosis Is Predictive of Overall Survival After Rituximab and Anthracyclines Based Regimen in Follicular Lymphoma

FS de Fontbrune, M.D., M. Sc., Danielle Canioni, MD, Hugo Chapdelaine, M.D., Richard Delarue, MD, Nicole Brousse, M.D., Felipe Suarez, MD, PhD, Olivier Hermine, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1601.
https://doi.org/10.1182/blood.V120.21.1601.1601
Published: 2012
Journal Articles

A Mendelian Predisposition to B Cell Lymphoma Caused by IL-10R2 Deficiency

Benedicte Neven, Emilie Mamessier, Julie Bruneau, Sophie Kaltenbach, Felipe Suarez, MD, PhD, Francois Doz, Daniel Orbach, Veronique Minard, Pierre Frange, MD, Danielle Canioni, MD, Isabelle Radford-Weiss, Vahid Asnafi, MD, PHD, jean-Laurent Casanova, Stephane Blanche, MD, Capucine Picard, MD, PhD, Frederic Rieux-Laucat, Frederic Davi, Nicole Brousse, M.D., Bertrand Nadel, PhD, Frank Ruemmele, Alain Fischer, MD/PhD
Journal: Blood
Blood (2012) 120 (21): 5092.
https://doi.org/10.1182/blood.V120.21.5092.5092
Published: 2012
Journal Articles

Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network ( MCL net )

Olivier Hermine, MD, PhD, Eva Hoster, Jan Walewski, Vincent Ribrag, MD, Nicole Brousse, M.D., Catherine Thieblemont, MD, PhD, Reda Bouabdallah, MD, Hartmut Dohner, MD, Pierre Feugier, MD, PhD, Roswitha Forspointner, MD, Corinne Haioun, MD, Michael Kneba, MD, PhD, Mathias Hänel, MD, Olivier Casasnovas, MD, Roland H. Mertelsmann, MD, PhD, Michael Hallek, MD, Andre Bosly, MD, PhD, M Nowacki, MD, Wolfram Klapper, MD PhD, Christian Gisselbrecht, MD, Bertrand Coiffier, MD, PhD, Michael Unterhalt, Wolfgang Hiddemann, MD, Martin H. Dreyling, MD
Journal: Blood
Blood (2012) 120 (21): 151.
https://doi.org/10.1182/blood.V120.21.151.151
Published: 2012